Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVAX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
NVAX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

NVAX Price Prediction Next Week

Technical Analysis: Based on the Fibonacci levels, NVAX is currently trading near its pivot point of $8.99, with immediate resistance at $9.55 and support at $8.44. The RSI(14) at 53.54 indicates neutral momentum, neither overbought nor oversold. The positive MACD of 0.05 suggests a slight bullish bias in the short term.

News Impact Analysis: Recent developments significantly affecting NVAX:

  1. Bird Flu Outbreak:
  • First U.S. death reported with 67 confirmed human cases
  • Novavax is developing vaccine candidates for bird flu
  • Potential opportunity as traditional vaccines target older strains
  1. Market Sentiment:
  • Recent weakness due to Moderna's lower 2025 revenue guidance
  • Stock dropped 9.8% to $8.40 on concerns about vaccine demand
  • Industry-wide challenges with post-pandemic market adaptation

Price Prediction for Next Week: Based on technical and news analysis:

Target Prices:

  • Resistance: $9.55 (Fibonacci R1)
  • Support: $8.44 (Fibonacci S1)
  • Expected Range: $8.44-$9.55

The stock is likely to trade between $8.44-$9.55 next week, with a higher probability of testing the resistance level due to:

  1. Positive momentum from bird flu vaccine development potential
  2. RSI indicating room for upward movement
  3. Positive MACD suggesting short-term bullish trend

Trading Recommendation: BUY at current levels ($8.99) with a target of $9.55 and stop loss at $8.44. The bird flu situation could provide positive catalyst, while technical indicators suggest potential upside movement within the defined range.

Technical Analysis: Based on the Fibonacci levels, NVAX is currently trading near its pivot point of $8.99, with immediate resistance at $9.55 and support at $8.44. The RSI(14) at 53.54 indicates neutral momentum, neither overbought nor oversold. The positive MACD of 0.05 suggests a slight bullish bias in the short term.

News Impact Analysis: Recent developments significantly affecting NVAX:

  1. Bird Flu Outbreak:
  • First U.S. death reported with 67 confirmed human cases
  • Novavax is developing vaccine candidates for bird flu
  • Potential opportunity as traditional vaccines target older strains
  1. Market Sentiment:
  • Recent weakness due to Moderna's lower 2025 revenue guidance
  • Stock dropped 9.8% to $8.40 on concerns about vaccine demand
  • Industry-wide challenges with post-pandemic market adaptation

Price Prediction for Next Week: Based on technical and news analysis:

Target Prices:

  • Resistance: $9.55 (Fibonacci R1)
  • Support: $8.44 (Fibonacci S1)
  • Expected Range: $8.44-$9.55

The stock is likely to trade between $8.44-$9.55 next week, with a higher probability of testing the resistance level due to:

  1. Positive momentum from bird flu vaccine development potential
  2. RSI indicating room for upward movement
  3. Positive MACD suggesting short-term bullish trend

Trading Recommendation: BUY at current levels ($8.99) with a target of $9.55 and stop loss at $8.44. The bird flu situation could provide positive catalyst, while technical indicators suggest potential upside movement within the defined range.

NVAX Similar Chart Price Prediction

The price of NVAX is predicted to go up 104.93%, based on the high correlation periods with NVVE. The similarity of these two price pattern on the periods is 91.05%.

stocks logo

NVAX

stocks logo

NVVE

Up: 104.93%Similarity: 91.05%

NVAX Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

NVAX Price Forecast($)

Potential Return(%)

2025

15.000

61.030

2026

15.000

61.030

2027

15.000

61.030

2028

15.000

61.030

2029

25.000

168.380

2030

25.000

168.380

What is NVAX stock price prediction 2025 ?

NVAX stock is predicted to reach $15-$18 by the end of 2025, driven by potential advancements in its vaccine portfolio, including bird flu and combination vaccines. The company's innovative recombinant nanoparticle technology positions it well for addressing emerging health crises. However, volatility in vaccine demand and competition from larger players may limit upside potential.

What is NVAX stock price prediction 2026 ?

NVAX stock is predicted to reach $15-$18 by 2026, driven by potential milestone payments from its Sanofi partnership and advancements in its COVID-19/influenza combination vaccine. However, risks include declining revenues and heavy reliance on a single product. The stock's speculative nature makes it highly volatile.

What is NVAX stock price prediction 2027 ?

NVAX stock is projected to reach approximately $15-$20 by 2027. This estimate is based on potential revenue growth from its COVID-19/influenza combination vaccine and milestone payments from the Sanofi partnership, despite current financial challenges and reduced guidance. However, the stock's speculative nature and reliance on successful execution of its pipeline make it a high-risk investment.

What is NVAX stock price prediction 2028 ?

NVAX stock is projected to reach approximately $15–$20 by 2028, assuming successful execution of its pipeline and partnerships, particularly the COVID-19/influenza combination vaccine. This estimate is based on potential milestone payments from the Sanofi collaboration and a gradual recovery in revenue. However, risks remain due to its reliance on a single product and ongoing restructuring efforts.

What is NVAX stock price prediction 2029 ?

The price prediction for NVAX stock in 2029 is estimated to be around $25-$30, assuming successful execution of its pipeline, including the COVID-19/influenza combination vaccine and other products. This projection is based on potential milestone payments, revenue growth from new products, and recovery in vaccine demand. However, risks such as competition, regulatory hurdles, and financial constraints could impact this forecast.

What is NVAX stock price prediction 2030 ?

NVAX stock price prediction for 2030 is highly speculative due to its volatile nature and dependency on vaccine demand. Assuming successful diversification and steady revenue growth, the stock could reach $25-$30, driven by potential milestones in its pipeline and partnerships like Sanofi. However, risks from competition and market conditions could limit upside.

NVAX Revenue Forecast

NVAX EPS Forecast

NVAX FAQs

What is bull‘s view on NVAX?

Novavax (NVAX) is currently trading at $11.24, up 15.2% recently, driven by heightened demand for vaccines amid rising respiratory illnesses and bird flu concerns. Bullish analysts highlight its innovative recombinant nanoparticle technology and potential government contracts, with a price target of $19, implying a 69% upside. Positive sentiment is also supported by its combination vaccine pipeline, which could streamline immunization efforts.

What is bear's view on NVAX?

Novavax (NVAX) is currently trading at $9.53, down 12% recently. Bears argue that the stock faces significant challenges due to its late entry into the COVID-19 vaccine market, missing initial demand, and ongoing revenue forecast cuts. Additionally, volatility from bird flu concerns and limited near-term market share growth further weigh on its outlook.

What is NVAX revenue forecast for next quarter？

The market consensus for NVAX's revenue in the upcoming quarter is projected to be approximately $47.5M USD.

What is NVAX eps forecast for next quarter？

The market consensus for NVAX's eps in the upcoming quarter is projected to be approximately $0.49 USD.

NVAX VS S&P500

Ask Intellectia about NVAX

NVAX Analyst's Forecast

Roger Song

Jefferies

Strong Buy

Price Target

$31 → $25

Upside

+146.31%

Jefferies lowered the firm's price target on Novavax to $25 from $31 and keeps a Buy rating on the shares after the company announced that the FDA has placed a clinical hold on the Investigational New Drug, or IND, application for its COVID-19-Influenza Combination, or CIC, and stand-alone influenza vaccine candidates. The clinical hold on the CIC candidate due to a serious adverse event, or SAE, seen in Phase 2 study was "a surprise given quite clean safety history," says the analyst, who believes the hold could be resolved into Phase 3 with significant upside if a trial is eventually successful, but also sees uncertainty on the timeline and increased risk.
Mayank Mamtani

B. Riley Securities

Strong Buy

Price Target

$23 → $26

Upside

+101.47%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free